

## CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE .....	9
Background .....	9
Objective and Scope .....	9
Selection of Topics for Monographs .....	10
Data for Monographs.....	11
The Working Group .....	11
Working Procedures.....	11
Exposure Data .....	12
Studies of Cancer in Humans .....	14
Studies of Cancer in Experimental Animals .....	17
Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	20
Summary of Data Reported.....	22
Evaluation .....	23
References .....	27
THE MONOGRAPH.....	33
<b>Introduction</b> .....	35
1. Scope of the monograph .....	35
2. Host-biomaterial interactions as related to carcinogenesis .....	37
2.1 Variables of the material or object .....	38
2.1.1 Intrinsic chemistry .....	38
2.1.2 Surface chemistry .....	38
2.1.3 Chemical nature of any released soluble components.....	39
2.1.4 Chemical or crystallographic nature of any released particulate components .....	39
2.1.5 Physical nature of any released particulate components .....	40
2.1.6 Size and shape .....	40
2.1.7 Surface energy and surface topography.....	41
2.1.8 Hardness of the material, its elastic moduli or the flexibility of the component.....	41
2.1.9 Electrical or magnetic properties of the material .....	41

2.1.10	Radioactivity .....	42
2.1.11	Sterilization procedures .....	42
2.2	Host variables .....	42
2.2.1	Species and strain .....	42
2.2.2	Age, sex and size of the animal .....	42
2.2.3	Site of implantation .....	43
2.2.4	Known risk factors for human cancer .....	43
2.2.5	Pharmacological status of a human host .....	43
2.2.6	Indication for clinical intervention and prior or coexistent disease .....	43
2.2.7	Latent period for tumour formation.....	43
2.3	Host–material system .....	44
3.	General mechanisms of solid-state carcinogenesis.....	45
3.1	Experimental implants in rodents.....	46
4.	Pathology of sarcomas, reactive and pseudoneoplastic conditions .....	49
4.1	Introduction .....	49
4.2	Incidence and etiology .....	49
4.3	Classification .....	51
4.4	Behaviour, grading and staging .....	53
4.5	Pseudosarcomas and reactive conditions .....	54
4.5.1	Reactions to injury .....	54
4.5.2	Reactions to foreign material.....	59
5.	General issues in epidemiological research on implants and cancer .....	60
5.1	Identification and selection of study population .....	61
5.2	Latency and length of follow-up .....	62
5.3	Statistical power .....	62
5.4	Exposure classification .....	62
5.5	Multiple hypothesis testing.....	62
5.6	Control for confounding influences .....	63
<b>1.</b>	<b>Exposure data .....</b>	<b>65</b>
1A.	<b>METALLIC MEDICAL AND DENTAL MATERIALS .....</b>	<b>65</b>
1A.1	Chemical and physical data .....	65
1A.1.1	Metallurgy .....	65
1A.1.2	Chemical composition of metals and alloys .....	67
1A.1.3	Chemical composition of dental casting alloys .....	75
1A.1.4	Dental amalgam .....	81
1A.1.5	Orthodontic metallic materials .....	81
1A.1.6	Analytical methods.....	81
1A.2	Production .....	82

1B.	NON-METALLIC MEDICAL AND DENTAL MATERIALS .....	84
1B.1	Chemical and physical data .....	84
1B.1.1	Polymer chemistry .....	84
1B.1.2	Synthesis and composition of polymers.....	85
1B.1.3	Ceramics .....	98
1B.1.4	Composite materials .....	99
1B.2	Production and use.....	99
1B.2.1	Production .....	99
1B.2.2	Use .....	101
1C.	COMPOSITE MEDICAL AND DENTAL IMPLANTS .....	102
1C.1	Description of devices .....	102
1C.1.1	Generic orthopaedic joint replacements.....	102
1C.1.2	Orthopaedic fracture fixation devices .....	103
1C.1.3	Cardiovascular devices.....	104
1C.1.4	Dental materials .....	104
1C.2	Numbers of implants used .....	105
1C.3	Regulations and guidelines .....	107
1D.	OTHER FOREIGN BODIES .....	109
1D.1	Introduction .....	109
1D.2	Bullets and pellets .....	109
1D.3	Shell fragments .....	110
<b>2.</b>	<b>Studies of cancer in humans .....</b>	<b>113</b>
2A.	METALLIC MEDICAL AND DENTAL MATERIALS .....	113
2A.1	Case reports .....	113
2A.2	Analytical studies.....	113
2B.	NON-METALLIC MEDICAL AND DENTAL MATERIALS .....	118
2B.1	Case reports .....	118
2B.1.1	Cancer following silicone implants for the breast ..	118
2B.1.2	Sarcomas at the site of vascular grafts.....	118
2B.2	Analytical studies.....	118
2B.2.1	Cohort studies.....	118
2B.2.2	Case-control studies.....	130
2C.	COMPOSITE MEDICAL AND DENTAL IMPLANTS .....	132
2C.1	Case reports .....	132
2C.1.1	Orthopaedic implants .....	132
2C.1.2	Cardiac pacemakers .....	132
2C.2	Analytical studies.....	146
2C.2.1	Orthopaedic implants .....	146
	(a) Cohort studies.....	146
	(b) Case-control studies.....	161

2D.	OTHER FOREIGN BODIES .....	162
2D.1	Metallic foreign bodies .....	162
2D.2	Non-metallic foreign bodies .....	162
<b>3.</b>	<b>Studies of cancer in animals seen in veterinary practice .....</b>	<b>173</b>
3.1	Dogs .....	173
3.1.1	Case reports .....	173
3.1.2	Analytical studies.....	173
3.2	Cats .....	173
3.2.1	Case reports .....	173
3.2.2	Case series .....	176
3.2.3	Analytical studies.....	177
<b>4.</b>	<b>Studies of cancer in experimental animals .....</b>	<b>179</b>
4A.	METALLIC MEDICAL AND DENTAL MATERIALS .....	179
4A.1	Metallic chromium.....	179
4A.1.1	Intrapleural administration .....	179
4A.1.2	Intramuscular administration .....	179
4A.1.3	Intraperitoneal administration .....	179
4A.1.4	Intravenous administration.....	180
4A.1.5	Intrarenal administration .....	180
4A.1.6	Intraosseous administration .....	181
4A.2	Metallic cobalt .....	181
4A.2.1	Intramuscular administration .....	181
4A.2.2	Intrarenal administration .....	182
4A.2.3	Intrathoracic administration .....	182
4A.2.4	Intraosseous administration .....	183
4A.3	Metallic nickel .....	183
4A.3.1	Inhalation exposure .....	183
4A.3.2	Intratracheal administration .....	184
4A.3.3	Intrapleural administration .....	184
4A.3.4	Subcutaneous administration .....	184
4A.3.5	Intramuscular administration .....	185
4A.3.6	Intraperitoneal administration .....	185
4A.3.7	Intraosseous administration .....	186
4A.3.8	Intrarenal administration .....	186
4A.3.9	Intravenous administration.....	186
4A.4	Metallic titanium .....	186
4A.4.1	Intramuscular administration .....	186
4A.4.2	Intraosseous administration .....	187
4A.5	Metallic foils .....	187
4A.5.1	Subcutaneous administration .....	187

4A.5.2	Intraperitoneal administration .....	187
4A.6	Metal alloys .....	188
4A.6.1	Intratracheal administration .....	188
4A.6.2	Intrabronchial administration .....	194
4A.6.3	Subcutaneous administration .....	194
4A.6.4	Intramuscular administration .....	194
4A.6.5	Intraperitoneal administration .....	196
4A.6.6	Intrarenal administration .....	196
4A.6.7	Intraosseous administration .....	197
4A.6.8	Intra-articular administration .....	197
4A.6.9	Implantation of ear tags .....	198
4B.	NON-METALLIC MEDICAL AND DENTAL MATERIALS .....	198
4B.1	Polydimethylsiloxanes (silicones) .....	198
4B.1.1	Subcutaneous administration .....	198
4B.1.2	Intraperitoneal administration .....	199
4B.1.3	Intraosseous implantation.....	200
4B.2	Polyurethane .....	200
4B.2.1	Subcutaneous and/or intraperitoneal administration .....	200
4B.2.2	Inhalation and/or intratracheal or intrabronchial administration .....	204
4B.3	Poly(methyl methacrylate).....	205
4B.3.1	Subcutaneous and/or intramuscular administration .....	205
4B.3.2	Intraperitoneal administration .....	207
4B.3.3	Other experimental systems .....	207
4B.4	Poly(2-hydroxyethyl methacrylate) .....	208
4B.4.1	Subcutaneous administration .....	208
4B.5	Poly(ethylene terephthalate) .....	208
4B.5.1	Subcutaneous administration .....	208
4B.6	Polyethylene.....	209
4B.6.1	Subcutaneous administration .....	209
4B.6.2	Intraperitoneal administration .....	211
4B.6.3	Other experimental systems .....	212
4B.7	Polypropylene .....	212
4B.7.1	Subcutaneous administration .....	212
4B.8	Polytetrafluoroethylene .....	213
4B.8.1	Subcutaneous administration .....	213
4B.8.2	Intraperitoneal administration .....	215
4B.9	Polyamide (nylon) .....	215
4B.9.1	Subcutaneous administration .....	215
4B.9.2	Intraperitoneal administration .....	215

4B.10	Poly(glycolic acid).....	216
4B.10.1	Subcutaneous administration .....	216
4B.11	Poly(lactide) .....	216
4B.11.1	Subcutaneous administration .....	216
4B.12	$\epsilon$ -Caprolactone-L-lactide copolymer .....	216
4B.12.1	Subcutaneous administration .....	216
4B.13	Polystyrene and related polymers .....	217
4B.13.1	Subcutaneous administration .....	217
4B.14	Poly(vinyl alcohol) .....	218
4B.14.1	Subcutaneous administration .....	218
4B.15	Poly(vinyl chloride).....	219
4B.15.1	Subcutaneous administration .....	219
4B.15.2	Other routes of administration .....	220
4B.16	Vinyl chloride–vinyl acetate copolymer .....	220
4B.16.1	Subcutaneous administration .....	220
4B.17	Cellophane .....	221
4B.17.1	Subcutaneous administration .....	221
4B.17.2	Other experimental systems .....	222
4B.18	Millipore filters .....	223
4B.18.1	Subcutaneous administration .....	223
4B.18.2	Intraperitoneal administration .....	224
4B.19	Epoxy resins.....	224
4B.19.1	Subcutaneous administration .....	224
4B.20	Aluminium oxide ceramics .....	224
4B.20.1	Subcutaneous administration .....	224
4B.21	Glass sheet .....	224
4B.21.1	Subcutaneous administration .....	224
4B.22	Major factors that affect tumour incidence .....	225
4B.22.1	Physical factors.....	225
4B.22.2	Chemical factors.....	227
4C.	COMPOSITE MEDICAL AND DENTAL IMPLANTS .....	228
4D.	OTHER FOREIGN BODIES .....	229
<b>5.</b>	<b>Other data relevant to an evaluation of carcinogenicity and its mechanisms</b> .....	<b>231</b>
5A.	METALLIC MEDICAL AND DENTAL MATERIALS .....	231
5A.1	Degradation of metallic implants in biological systems .....	231
5A.1.1	Mechanisms of degradation .....	231
5A.1.2	In-vitro corrosion of dental alloys .....	232
5A.2	Absorption, distribution and excretion .....	233
5A.2.1	Humans.....	234
5A.2.2	Experimental systems.....	235

5A.3	Tissue responses and other expressions of toxicity.....	237
5A.3.1	Humans.....	237
	(a) Inflammatory and immunological responses ..	237
	(b) Oral contact lichenoid reactions.....	238
	(c) Allergic reactions .....	239
5A.3.2	Experimental systems.....	240
	(a) Animal studies .....	240
	(b) Cytotoxicity of metal ions .....	241
	(c) Cytotoxicity of metallic materials .....	242
	(d) Effects of metal ions and metallic materials on cytokine levels and histamine release .....	242
5A.4	Genetic and related effects.....	242
5A.4.1	Humans.....	242
5A.4.2	Experimental systems.....	243
5A.5	Mechanisms of carcinogenic action.....	245
5B.	NON-METALLIC MEDICAL AND DENTAL MATERIALS .....	245
5B.1	Degradation, distribution, metabolism and excretion .....	245
5B.1.1	Humans.....	245
	(a) Degradation of polyurethane foam.....	245
	(b) Wear of dental composites .....	248
5B.1.2	Experimental systems.....	249
	(a) Polyurethane-coated breast implants .....	249
	(b) Other polyurethane implants .....	250
	(c) Polydimethylsiloxanes (silicones) .....	251
	(d) Degradable polymers .....	252
	(e) Substances released from dental composites ..	253
5B.2	Tissue responses and other expressions of toxicity.....	255
5B.2.1.	Humans.....	255
	(a) Polydimethylsiloxanes (silicones) .....	255
	(b) Polyurethane-coated breast implants .....	257
	(c) Polytetrafluoroethylene implants .....	257
	(d) Joint replacements, polyethylene and bone cement .....	257
	(e) Dental materials .....	258
5B.2.2	Experimental systems.....	263
	(a) Inflammatory, hyperplastic and metaplastic responses.....	263
	(i) Polydimethylsiloxanes (silicones) .....	263
	(ii) Polyurethanes .....	264
	(iii) Polyethylene.....	265
	(iv) Polytetrafluoroethylene .....	266
	(v) Acrylic substances .....	266

	(vi) Ceramics, hydroxylapatite .....	267
	(vii) Dental composites .....	268
	(viii) Components of dental composites .....	270
	(ix) Other materials.....	275
	(b) Immunological effects .....	275
	(i) Polydimethylsiloxanes (silicones) .....	275
	(ii) Other materials.....	276
5B.3	Genetic and related effects.....	277
5B.3.1	Humans.....	277
5B.3.2	Experimental systems.....	277
	(a) In-vitro genotoxicity assays .....	277
	(b) Cell transformation test .....	280
	(c) In-vivo genotoxicity assays .....	281
	(d) Cytogenetic effects in tumour cells .....	282
5B.4	Mechanistic considerations of implantation-site sarcomagenesis in rodents .....	282
5B.4.1	Major features that affect tumour incidence in solid-state carcinogenesis .....	282
5B.4.2	Biological factors .....	282
	(a) Fibrous tissue capsule formation and continued presence of implant .....	282
	(b) The role of perforation in the reduction of tumorigenicity.....	283
	(c) Species and strain differences .....	283
5B.4.3	Timing and location of preneoplastic events .....	284
5B.4.4	Origin of preneoplastic parent cells .....	286
5B.4.5	Stages in foreign-body tumorigenesis .....	287
5B.4.6	Other data on the role of capsule and implant on tumour promotion/progression.....	288
	(a) Different roles of an implant during early and late stages of carcinogenesis .....	288
	(b) Promotion by an implant of subcutaneous carcinogenesis initiated by irradiation or a chemical carcinogen .....	289
5B.4.7	Effect of different implant materials on inhibition of gap-junctional intercellular communication as an index of tumour promotion .....	290
5B.4.8	What initiates the formation of preneoplastic parent cells? .....	293
5B.4.9	Possible genotoxic mechanisms underlying solid-state carcinogenesis .....	294



5C.	OTHER FOREIGN BODIES .....	297
5C.1	Degradation in biological systems.....	297
5C.2	Distribution and excretion .....	297
5C.2.1	Lead .....	297
	(a) Humans .....	297
	(b) Experimental systems.....	298
5C.2.2	Depleted uranium .....	298
	(a) Humans .....	298
	(b) Experimental systems.....	299
5C.3	Tissue responses and other expressions of toxicity.....	300
5C.3.1	Lead .....	300
5C.3.2	Depleted uranium .....	300
5C.4	Genetic and related effects.....	301
5C.4.1	Lead .....	301
5C.4.2	Depleted uranium .....	301
<b>6.</b>	<b>Summary of data reported and evaluation.....</b>	<b>303</b>
6.1	Exposure data .....	303
6.2	Human carcinogenicity data .....	304
6.3	Veterinary studies .....	305
6.4	Animal carcinogenicity data.....	306
6.5	Other relevant data .....	308
6.6	Evaluation .....	309
<b>Appendix</b>	.....	<b>313</b>
	Asbestos fibres .....	313
	Crystalline silica .....	317
	Poorly soluble particulates (PSPs) or low-toxicity dusts .....	319
	Relevance of these mechanisms for evaluation of the carcinogenicity of surgical implants and prosthetic devices .....	320
<b>References</b>	.....	<b>323</b>
<b>CUMULATIVE INDEX TO THE MONOGRAPHS SERIES .....</b>		<b>377</b>

## NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.